Loading...

Fortress Biotech

DB:CNB
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNB
DB
$90M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Fortress Biotech has significant price volatility in the past 3 months.
CNB Share Price and Events
7 Day Returns
84.3%
DB:CNB
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-27%
DB:CNB
-9.2%
DE Biotechs
-6.7%
DE Market
CNB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fortress Biotech (CNB) 84.3% 50.2% 139.5% -27% -30% 98.5%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • CNB underperformed the Biotechs industry which returned -9.2% over the past year.
  • CNB underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
CNB
Industry
5yr Volatility vs Market

CNB Value

 Is Fortress Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fortress Biotech. This is due to cash flow or dividend data being unavailable. The share price is €2.539.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fortress Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fortress Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CNB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.68
NasdaqCM:FBIO Share Price ** NasdaqCM (2019-04-18) in USD $1.62
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fortress Biotech.

DB:CNB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:FBIO Share Price ÷ EPS (both in USD)

= 1.62 ÷ -1.68

-0.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fortress Biotech is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Fortress Biotech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Fortress Biotech's expected growth come at a high price?
Raw Data
DB:CNB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-33.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fortress Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fortress Biotech's assets?
Raw Data
DB:CNB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.03
NasdaqCM:FBIO Share Price * NasdaqCM (2019-04-18) in USD $1.62
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:CNB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:FBIO Share Price ÷ Book Value per Share (both in USD)

= 1.62 ÷ 0.03

50.63x

* Primary Listing of Fortress Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fortress Biotech is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Fortress Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Fortress Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CNB Future Performance

 How is Fortress Biotech expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-33.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fortress Biotech expected to grow at an attractive rate?
  • Unable to compare Fortress Biotech's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Fortress Biotech's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Fortress Biotech's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CNB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CNB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -33.9%
DB:CNB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 2.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CNB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CNB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 28 -155 1
2019-12-31 27 -133 1
DB:CNB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 27 -99 -73
2018-09-30 228 -103 -70
2018-06-30 211 -105 -80
2018-03-31 198 -102 -76
2017-12-31 17 -81 -65
2017-09-30 155 -78 -74
2017-06-30 109 -62 -60
2017-03-31 61 -46 -55
2016-12-31 16 -46 -55
2016-09-30 4 -35 -50
2016-06-30 3 -31 -55
2016-03-31 1 -30 -49

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fortress Biotech is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Fortress Biotech's revenue is expected to grow by 2.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CNB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Fortress Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CNB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -2.49 -2.49 -2.49 1.00
2019-12-31 -2.28 -2.28 -2.28 1.00
DB:CNB Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.68
2018-09-30 -1.59
2018-06-30 -1.87
2018-03-31 -1.80
2017-12-31 -1.55
2017-09-30 -1.83
2017-06-30 -1.48
2017-03-31 -1.37
2016-12-31 -1.38
2016-09-30 -1.25
2016-06-30 -1.39
2016-03-31 -1.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fortress Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Fortress Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fortress Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CNB Past Performance

  How has Fortress Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fortress Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fortress Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fortress Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fortress Biotech's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Fortress Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fortress Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CNB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 26.88 -73.01 53.37 87.38
2018-09-30 228.27 -69.68 72.08 76.74
2018-06-30 211.46 -80.16 74.75 73.14
2018-03-31 198.33 -75.91 73.05 69.14
2017-12-31 17.25 -64.55 48.70 52.49
2017-09-30 154.88 -73.89 57.45 48.65
2017-06-30 108.97 -59.76 47.06 40.78
2017-03-31 60.50 -54.87 39.46 35.72
2016-12-31 16.48 -55.10 32.92 35.13
2016-09-30 4.20 -49.70 32.12 30.32
2016-06-30 3.25 -54.88 30.35 33.00
2016-03-31 1.02 -48.58 25.53 28.55
2015-12-31 0.86 -48.43 21.58 29.81
2015-09-30 0.53 -40.11 17.57 25.10
2015-06-30 0.50 -26.54 13.21 16.41
2015-03-31 0.50 -25.07 11.81 14.81
2014-12-31 -20.39 10.41 10.24
2014-09-30 -26.47 10.19 13.93
2014-06-30 -29.71 9.60 16.98
2014-03-31 -35.67 9.71 22.40
2013-12-31 -37.16 10.10 25.68
2013-09-30 -36.03 9.81 23.71
2013-06-30 -34.13 9.72 22.12
2013-03-31 -29.91 9.15 18.86
2012-12-31 -27.61 8.67 17.47
2012-09-30 -25.66 7.77 16.34
2012-06-30 -23.10 7.50 14.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fortress Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fortress Biotech has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fortress Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fortress Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fortress Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CNB Health

 How is Fortress Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fortress Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fortress Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fortress Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fortress Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fortress Biotech Company Filings, last reported 3 months ago.

DB:CNB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 19.74 79.50 83.11
2018-09-30 84.64 84.26 123.17
2018-06-30 96.27 84.03 136.36
2018-03-31 107.55 86.10 165.23
2017-12-31 120.50 62.50 130.95
2017-09-30 121.27 63.62 156.03
2017-06-30 150.62 46.95 167.58
2017-03-31 126.32 33.03 135.14
2016-12-31 82.97 28.22 90.51
2016-09-30 74.84 27.40 84.72
2016-06-30 58.21 21.81 71.34
2016-03-31 70.91 20.75 81.42
2015-12-31 84.27 23.17 98.18
2015-09-30 54.92 23.29 65.51
2015-06-30 55.21 23.23 61.04
2015-03-31 60.19 24.01 68.93
2014-12-31 70.52 14.00 69.76
2014-09-30 69.26 14.01 71.64
2014-06-30 72.37 14.01 76.09
2014-03-31 75.49 14.01 79.98
2013-12-31 81.28 13.22 99.52
2013-09-30 87.51 14.87 106.27
2013-06-30 48.56 14.77 67.89
2013-03-31 26.73 14.28 44.05
2012-12-31 22.03 14.19 40.20
2012-09-30 29.13 14.09 47.48
2012-06-30 33.82 0.75 38.21
  • Fortress Biotech's level of debt (402.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (16.3% vs 402.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fortress Biotech has less than a year of cash runway based on current free cash flow.
  • Fortress Biotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 42.8% each year.
X
Financial health checks
We assess Fortress Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fortress Biotech has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CNB Dividends

 What is Fortress Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fortress Biotech dividends.
If you bought €2,000 of Fortress Biotech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fortress Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fortress Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CNB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CNB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fortress Biotech has not reported any payouts.
  • Unable to verify if Fortress Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fortress Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fortress Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Fortress Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fortress Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fortress Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CNB Management

 What is the CEO of Fortress Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lindsay Rosenwald
COMPENSATION $2,069,989
AGE 63
TENURE AS CEO 5.3 years
CEO Bio

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Executive Chairman, Chief Executive Officer and President of Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) since December 19, 2013. Over the 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald has experience in creating, financing and investing in biotechnology and life-sciences companies and has been an investment banker, venture capitalist and fund Manager. Dr. Rosenwald served as the Co-Chairman and Chief Executive Officer of Origo Acquisition Corporation (alternative name CB Pharma Acquisition Corp.) from August 26, 2014 to June 10, 2016. Dr. Rosenwald joined CB Pharma Acquisition Corp in 2014. Dr. Rosenwald is the Founder of Paramount BioSciences, LLC. and serves as its Chairman and Chief Executive Officer. Dr. Rosenwald is the Founder of Paramount Capital Inc. and serves as its Chief Executive Officer and Chairman. Dr. Rosenwald is the Founder of Interneuron Pharmaceuticals Inc. and serves as its Chairman. He is the General Partner at Aries Domestic Fund LP. He is the Founder of Greenwich Therapeutics, Inc. Dr. Rosenwald is the Founder of Paramount BioCapital Asset Management, Inc. He is Founder of Paramount BioCapital, Inc. He served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc from November 2014 to August 2015. Dr. Rosenwald serves as Co-Portfolio Manager and Partner of Opus Point Partners Management, LLC (“Opus Point”), an asset management firm in the life sciences industry, which he co-founded in 2009. Over the 23 years, Dr. Rosenwald acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald has been Chief Executive Officer at Paramount BioCapital, Inc. since 1991. Dr. Rosenwald served as Chief Executive Officer and Chairman at Paramount BioCapital Asset Management, Inc. from 1994 to 2008. He served as Chief Executive Officer and President of Avenue Therapeutics, Inc. from November 2014 to August 2015 and has been its Executive Chairman since February 2015. He serves as Executive Chairman of the Board at Helocyte Inc. From 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. He also served as managing Member of Paramount Biosciences LLC (and its predecessor, Paramount BioCapital Investments, LLC), an entity engaged in the research, formation and acquisition of seed-stage and distressed life science technologies and companies, identifying and evaluating a broad spectrum of therapeutic and medical technologies in order to capture innovations with significant commercial potential from 1996 to 2008. He also has biotechnology and pharmaceutical industry experience and in-depth understanding of business. He co-founded Endo Pharmaceuticals Solutions Inc. (formerly Indevus Pharmaceuticals Inc.). He was employed at Neose Technologies, Inc. He served as the Founder, Chief Executive Officer and Chairman at Paramount Capital Investments, L.L.C. He founded numerous biopharmaceutical companies and serves as an Officer or Director at several privately held biopharmaceutical companies. Dr. Rosenwald served as the Chairman at Indevus Pharmaceuticals from February 1989 to January 19, 2000. He serves as Chairman of the Board of Paramount Capital Asset Management, Inc. Dr. Rosenwald served as Chairman of the Board of Paramount Acquisition Corp. since October 2005 until its merger with B.J.K. Inc. in October 2007. He served as Chairman of Chem Rx Corporation since June 1, 2005. He serves as a Director at Helocyte Inc. He has been Non-Executive Director of Mustang Bio Inc. since March 13, 2015. He serves as a Member of the Board of Directors of, Avigen Inc.; BioCryst Pharmaceuticals Inc.; Titan Pharmaceuticals Inc.; VimRx Pharmaceuticals Inc.; Neose Technologies Inc. and Access Oncology. He has been a Non-Executive Director of Checkpoint Therapeutics, Inc. since November 10, 2014. Dr. Rosenwald has been a Director of Fortress Biotech, Inc. since October 2009. Dr. Rosenwald has been a Director of Coronado BioSciences, Inc. since October 2009. He served as a Director of Keryx Biopharmaceuticals Inc., since March 2000 until November 2006. He served as a Director of Endo Pharmaceuticals Solutions Inc. He served as a Director of Cougar Biotechnology, Inc. since May 2003 until July 18, 2007. He served as a Director of Chem Rx Corporation since June 1, 2005 until January 2008. Prior thereto, he served as a Member of the Board of Directors of Indevus Pharmaceuticals Inc., until August 29, 2003 and Sparta Pharmaceuticals since February 1991. Dr. Rosenwald serves as a Member of the Board of Directors of Aevitas Therapeutics, Inc., Caelum Biosciences, Inc., Cellvation, Inc., Journey Medical Corporation and Tamid Bio, Inc. Dr. Rosenwald received a B.S. in Finance from Pennsylvania State University and an M.D. from Temple University School of Medicine.

CEO Compensation
  • Lindsay's compensation has increased whilst company is loss making.
  • Lindsay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Fortress Biotech management team in years:

5.6
Average Tenure
61
Average Age
  • The average tenure for the Fortress Biotech management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Lindsay Rosenwald

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
63
TENURE
5.3 yrs

Eric Rowinsky

TITLE
Co-Vice Chairman
COMPENSATION
$555K
AGE
61
TENURE
8.5 yrs

Mike Weiss

TITLE
Executive Vice Chairman of Strategic Development
COMPENSATION
$2M
AGE
52
TENURE
5.2 yrs

Robyn Hunter

TITLE
CFO, Treasurer & Corporate Secretary
COMPENSATION
$2M
AGE
56
TENURE
1.8 yrs

George Avgerinos

TITLE
Senior Vice President of Biologics Operations
COMPENSATION
$675K
AGE
64
TENURE
5.8 yrs

Thomas Schaible

TITLE
Project Leader of Inflammatory Bowel Disease
TENURE
5.9 yrs
Board of Directors Tenure

Average tenure and age of the Fortress Biotech board of directors in years:

5.2
Average Tenure
62
Average Age
  • The tenure for the Fortress Biotech board of directors is about average.
Board of Directors

Lindsay Rosenwald

TITLE
Executive Chairman
COMPENSATION
$2M
AGE
63
TENURE
5.3 yrs

Eric Rowinsky

TITLE
Co-Vice Chairman
COMPENSATION
$555K
AGE
61
TENURE
8.5 yrs

Mike Weiss

TITLE
Executive Vice Chairman of Strategic Development
COMPENSATION
$2M
AGE
52
TENURE
5.2 yrs

J. Lobell

TITLE
Director
COMPENSATION
$338K
AGE
55
TENURE
12.8 yrs

Dov Klein

TITLE
Director
COMPENSATION
$330K
AGE
66
TENURE
3.8 yrs

Jimmie Harvey

TITLE
Director
COMPENSATION
$318K
AGE
66
TENURE
10.3 yrs

Mark Lowdell

TITLE
Member of Scientific Advisory Board
AGE
55

Malcolm Hoenlein

TITLE
Director
COMPENSATION
$170K
AGE
74
TENURE
5.2 yrs

Joel Weinstock

TITLE
Scientific Advisor
TENURE
1.8 yrs

David Elliott

TITLE
Scientific Advisor
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Dec 18 Sell George Avgerinos Individual 11. Dec 18 11. Dec 18 -97,325 €0.93 €-90,245
30. Nov 18 Sell Robyn Hunter Individual 23. Nov 18 23. Nov 18 -20,370 €1.14 €-23,179
X
Management checks
We assess Fortress Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fortress Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CNB News

Simply Wall St News

CNB Company Info

Description

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Details
Name: Fortress Biotech, Inc.
CNB
Exchange: DB
Founded: 2006
$79,620,344
61,302,251
Website: http://www.fortressbiotech.com
Address: Fortress Biotech, Inc.
2 Gansevoort Street,
9th Floor,
New York,
New York, 10014,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM FBIO Common Stock Nasdaq Capital Market US USD 17. Nov 2011
DB CNB Common Stock Deutsche Boerse AG DE EUR 17. Nov 2011
NasdaqCM FBIO.P 9.375% CUM PFD A Nasdaq Capital Market US USD 14. Nov 2017
Number of employees
Current staff
Staff numbers
88
Fortress Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.